A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Inclusion Criteria: Histologically or cytologically confirmed diagnosis of Stage IIIB, IIIC, or Stage IV (M1a, M1b, or M1c) NSCLC Subjects who have NSCLC with known actionable genomic alteration (AGAs) are permitted Participants must only have received the following prior therapies in the locally advanced recurrent or metastatic setting: Participants without AGAs must have received prior treatment with platinum-based chemotherapy and a PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy), unless contraindicated. Participants with AGAs must have received no more than 2 applicable targeted therapies and must have received prior treatment with platinum-based chemotherapy. May also have received up to one PD(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy). Measurable disease based on RECIST v1.1 Eastern cooperative Oncology Group (ECOG) performance status score of 0 or 1 Exclusion Criteria: Life expectancy of less than (<) 3 months Known allergies/hypersensitivity/intolerance to or contraindication of taxanes, docetaxel, or any excipient contained in the drug formulation of SGN-B6A History of another malignancy within 3 years before Cycle 1 Day 1, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death Participants with any of the following respiratory conditions: Evidence of noninfectious interstitial lung disease (ILD) or pneumonitis that: Was previous diagnosed and required systemic steroids, or Is currently diagnosed and managed, or Is suspected on radiologic imaging at screening Known diffusing capacity of the lung for carbon monoxide (DLCO) < 50% Any Grade greater than or equal to (≥) 3 pulmonary disease unrelated to underlying malignancy Pre-existing peripheral neuropathy Grade greater than or equal to (≥) 2 Uncontrolled diabetes mellitus Prior therapy: Any prior treatment with docetaxel or MMAE-derived drugs At least 14 days must have elapsed from the last dose of radiotherapy until Cycle 1 Day 1. Prior radiation therapy to the lung parenchyma that is >30 Gray (Gy) within 6 months of Cycle 1 Day 1. Any systemic anticancer therapy (standard or experimental) within 21 days prior to Cycle 1 Day 1. Active central nervous system (CNS) lesions, including leptomeningeal metastasis, are excluded. Participants with definitively treated brain metastases are eligible in they meet the following criteria: Have been clinically stable for at least 4 weeks prior to treatment initiation and baseline scans show no evidence of new or enlarged metastasis On a stable dose of less than or equal to (≤) 10mg/day of prednisone or equivalent for a least 2 weeks (if requiring steroid treatment) Treatment with corticosteroids greater than (>) 1 month prior to Screening visit No evidence of clinical and radiographic disease progression in the CNS for ≥ 21 days after definitive radiotherapy and/or surgery